SCHEMBL22835753

SCHEMBL22835753

O=C(O)c1ncn2cccnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 4/20 0.40
MAPT P10636 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
TSHR P16473 2/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
BLM P54132 1/20 0.40
AGER Q15109 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
APOBEC3A P31941 2/20 0.38
APOBEC3G Q9HC16 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
MYC P01106 1/20 0.37
CYP1A2 P05177 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
LMNA P02545 3/20 0.34
NAPRT Q6XQN6 3/20 0.34
P4HTM Q9NXG6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10473780 0.84 IRAK4 (0.42) KDM4EALDH1A1MAPTTSHRBLM
SCHEMBL22835691 0.80 L3MBTL1 (0.46) KDM4EALDH1A1MAPTL3MBTL1ALOX15
SCHEMBL3528247 0.76 NUDT1 (0.45) KDM4EALDH1A1MAPTL3MBTL1TSHR
SCHEMBL29481683 0.75 NUDT1 (0.33) KDM4EALDH1A1MAPTL3MBTL1TSHR
SCHEMBL16416782 0.70 KDM4E (0.50) KDM4EALDH1A1MAPTL3MBTL1TSHR
SCHEMBL415747 0.70 TSHR (0.42) KDM4EALDH1A1MAPTL3MBTL1TSHR
SCHEMBL5496407 0.68 NUDT1 (0.56) KDM4EALDH1A1PARP1KMT2AHPGD
SCHEMBL23744915 0.68 PIK3CG (0.32)
SCHEMBL29154276 0.68 KDM4E (0.38) KDM4EALDH1A1MAPTTSHRTDP1
SCHEMBL18365964 0.67 TAS2R14 (0.37) ALDH1A1MAPTTSHRGAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 US disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 US disclosed
CN-115867552-B Imidazo pyrimidine derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-12-13 CN disclosed
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-02-22 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
CN-115867552-A Imidazolopyrimidine derivative, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2023-03-28 CN disclosed
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-02 US disclosed
EP-4100004-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-12-14 EP disclosed
EP-3989966-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-05-04 EP disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed
CN-104193745-A Imidazolopyrimidine carboxylic acid type compound and preparation method thereof SPHINX SCIENT LAB CORP 2014-12-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 KDM4E 240/4885ALDH1A1 4348/4885MAPT 3470/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 KDM4E 628/4885ALDH1A1 3721/4885MAPT 4151/4885
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885MAPT 2459/4885
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885MAPT 2459/4885
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF IRAK4, IRAK2, IRAK3 KDM4E 87/4885ALDH1A1 3918/4885MAPT 1491/4885
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885MAPT 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.